Search

Displaying results 901 - 910 of 4207 in total
  1. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. … Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond.

  2. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]

  3. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

  4. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

  5. Drug

    Aluminum hydroxide

    go.drugbank.com/drugs/DB06723
    ApprovedInvestigational

    It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.

  6. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].

  7. Drug

    Vasopressin

    go.drugbank.com/drugs/DB00067
    ApprovedInvestigational

    [A228013] Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting … [A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413]

  8. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

  9. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

  10. Drug

    Tagatose

    go.drugbank.com/drugs/DB04936
    Investigational

    It is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener. … Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.